About our guidance We use the best available evidence to develop guidance to improve health and social care. Our guidance takes many forms: NICE guidelines (clinical, social care, public health, ...

Social care We work with the adult and children's care sectors to develop independent recommendations for social care. We develop health and public health advice and guidance, which allows an ...

NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

Type 2 diabetes in adults: management (medicines update)F10: This contains the NMA report for NMAs on binary outcomes (cardiovascular mortality, 3-item MACE, 4-item MACE, 5-item MACE, non-fatal ...

Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any ...

Tarlatamab (IMDYLLTRA, Amgen) is indicated for 'the treatment of adult patients with extensive-stage small-cell lung cancer (ES‑SCLC) with disease progression on or after at least two prior lines of ...

Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults ...